Amplyx Pharmaceuticals, Inc.

UEI: N4A8X52DCND5
CAGE: 4TDM0
Primary NAICS: 541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration: Expired Oct 12, 2022

Company facts

Self-certified in SAM.gov: For Profit Organization
Entity structure: Corporate Entity (Not Tax Exempt)
SAM.gov registration date: Jul 11, 2007
Website: pfizer.com
Founded: 1849
Employees: 50K-100K
Estimated annual revenue: $10B+
Industry: Health Care

Pharmaceuticals, Biotechnology & Life Sciences

Pharmaceuticals
SIC code: 28 Chemical & Allied Products
Profiles: LinkedIn

X

Facebook

Crunchbase

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated Apr 2, 2023.

Award	Agency	Obligated	Awarded
Clinical trial W81XWH18C0074	Medical Command (Army)	$2,734,526	Mar 6, 2018

Award	Agency	Obligated	Awarded
Developing a novel antifungal targeting GWT1 for the treatment of invasive aspergillosis and rare mold infections R44AI131864	National Institute of Allergy and Infectious Diseases (NIH)	$1,457,638	Aug 18, 2017
Developing a novel, fungicidal therapeutic to treat coccidioidomycosis R44AI125017	National Institute of Allergy and Infectious Diseases (NIH)	$1,460,969	Jul 1, 2016
Discovering a targeted inositol phosphorylceramide synthase inhibitor to improve R43AI112467	National Institutes of Health	$225,000	Feb 5, 2014
Developing a new therapeutic for the treatment of invasive aspergillosis R44AI106235	National Institutes of Health	$1,476,417	Jul 18, 2013
Developing a new therapeutic for the treatment of invasive aspergillosis R43AI106235	National Institutes of Health	$599,104	Jul 18, 2013

Amplyx Pharmaceuticals, Inc.'s SAM.gov registration expired on October 12, 2022.

Amplyx Pharmaceuticals, Inc.'s most recent federal contract award is Clinical trial (W81XWH18C0074), from Medical Command (Army), on March 6, 2018.

On GovTribe

Try for free Login